久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實(shí)業(yè)有限公司Logo

熱門詞: 進(jìn)口電動(dòng)溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動(dòng)溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動(dòng)高溫調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)高溫法蘭調(diào)節(jié)閥進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥

當(dāng)前位置: 首頁(yè) > 所有品牌 > Seattle Genetics
Seattle Genetics
Seattle Genetics Seattle Genetics

美國(guó)Seattle Genetics 
Seattle Genetics公司是美國(guó)的一家專業(yè)研發(fā)治療腫瘤和免疫類疾病的單克隆抗體藥物的生物技術(shù)公司。該公司在抗體偶聯(lián)技術(shù)方面比較有優(yōu)勢(shì),正在研發(fā)多種偶聯(lián)抗癌劑的抗體藥物。

At Seattle Genetics, we are committed to developing innovative antibody-based therapies that improve clinical outcomes for patients with cancer and autoimmune diseases. We are dedicated to addressing unmet medical need, and strive to achieve that goal through an unwavering commitment to excellence in clinical development. Focusing on Clinical Development
Seattle Genetics is a clinical stage biotechnology company advancing a broad product pipeline of antibody-based therapies. Our lead program, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the FDA for patients with relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is empowered by Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. In addition, we are conducting clinical trials with four other product candidates, lintuzumab (SGN-33), dacetuzumab (SGN-40) and SGN-75, for the treatment of cancer, and SGN-70, for autoimmune diseases. We are also advancing a pipeline of promising preclinical candidates and have robust research and development capabilities that are our engine for innovation and long-term growth.

Our proprietary ADC technology empowers antibodies by stably linking them to cell-killing drug payloads. The drug payload is inactive until released from the antibody inside the targeted cancer cell, thereby sparing normal tissue the toxicity of traditional chemotherapy. In addition to brentuximab vedotin, SGN-75 is an ADC that is in a phase I clinical trial and we are developing several preclinical ADC product candidates, including ASG-5ME, which is advancing towards a planned 2010 clinical trial for solid tumors.

Expanding Our Opportunities Through Collaboration
Collaborating with leading biopharmaceutical companies is a cornerstone of Seattle Genetics' business strategy. Product-focused collaborations, such as our exclusive worldwide collaboration agreement with Genentech (a wholly owned member of the Roche Group) to develop and commercialize dacetuzumab, provide significant near- and mid-term funding while bringing in additional resources and expertise to support, advance and expand promising development programs. Collaboration and license agreements around our proprietary ADC technology also generate cash for the company - more than $75 million to date - while providing further clinical validation of the ADC platform and, in some cases, opening the door to new product development opportunities.
 

關(guān)于我們客戶服務(wù)產(chǎn)品分類法律聲明
主站蜘蛛池模板: 国产亚洲免费观看 | 国产高清一区二区三区视频 | 久久精品国内一区二区三区 | 国产免费三a在线 | 一级一黄在线观看视频免费 | 成人精品视频一区二区三区 | 国产精品免费_区二区三区观看 | 国产一区导航 | 国产成人在线看 | 亚洲一区二区久久 | 97久久精品午夜一区二区 | 国产第一页精品 | 欧美日本道免费一区二区三区 | 看全色黄大色大片免费久久久 | 国产成人精品一区二区三区… | 亚洲一区二区精品 | 欧美在线看欧美视频免费网站 | 欧美精品第一页 | 欧美另类第一页 | 国产免费一区二区三区香蕉精 | 久久伊人精品一区二区三区 | 欧美日韩性生活 | 大香伊人中文字幕精品 | 国产成人精品日本亚洲专区6 | 欧美性第一页 | 欧美在线视频免费 | 亚洲精品一二三四区 | 一级一级特黄女人精品毛片视频 | 婷婷在线免费视频 | 亚洲色图欧美色 | 精品久久久久久久中文字幕 | 欧美电影一区二区 | 欧美 日韩 亚洲另类专区 | 在线播放国产一区二区三区 | 在线免费观看国产 | 国产欧美视频在线观看 | 日韩精品免费视频 | 国产精品免费播放 | 日日天天| 看真人视频一级毛片 | 午夜视频免费看 |